Back to Home

CSL

ASX: CSL $386.14 USD~$75B MCAP

Services: Global biopharmaceutical group; CSL Behring develops plasma-derived and recombinant therapeutic products for bleeding disorders, immune deficiencies, CIDP, hereditary angioedema, and Alpha-1 Antitrypsin Deficiency; Seqirus produces influenza vaccines; CSL Vifor addresses iron deficiency and nephrology

Company Info

Sector:Plasma-derived Therapies / Vaccines
Headquarters:Parkville, Melbourne, Australia
Founded:1916
Website:www.csl.com/

Upcoming Milestones & Key Dates

Q3/Q4 2026
Earnings

Q2 2026 earnings call

Recent News

No recent news updates available for this company.

Leadership Team

Careers & Job Openings

Developer, Clinical Data Applications & EDC Systems

N/A
King of Prussia, PA
Apply Now

Sr. Director, Global Brand & Portfolio Management

N/A
Summit, NJ
Apply Now

Project Engineering, Associate Director

N/A
Kankakee, IL
Apply Now